Document Detail


5-hydroxtryptamine receptors in systemic hypertension: an arterial focus.
MedLine Citation:
PMID:  20433685     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Serotonin (5-hydroxytryptamine [5-HT]) was named for its isolation from blood serum (sero-) and ability to contract smooth muscle (-tonin). Thus, its relationship with the cardiovascular system began with its discovery.
AIMS: This review will focus on the effects of 5-HT and its receptors in the vasculature, with a focus on their involvement in high blood pressure (hypertension). Two seemingly contradictory bodies of evidence exist that make it difficult to assign any one function to 5-HT in vascular control of blood pressure.
RESULTS:  In vitro, 5-HT is an established vasoconstrictor, the effects of which are amplified in hypertension. By contrast, 5-HT (or its precursor 5-hydroxytryptophan) lowers blood pressure when given chronically in vivo. We will discuss ideas that might help us understand these differences, discuss relatively new pharmacology parameters (e.g. biased, inverse agonism) as they pertain to 5-HT receptors, and pose questions that are vital to answer so as to understand the role played by 5-HT in control of blood pressure, especially as it pertains to vascular function.
CONCLUSIONS: Our goal is to understand if the actions of 5-HT in hypertension are physiologically and clinically relevant. The community understands 5-HT has complex cardiovascular effects, and clinical studies have proven equivocal in terms of the involvement of 5-HT. This article provides a balanced view of evidence/literature that illustrates involvement of 5-HT in hypertension as controversial. It contributes new pharmacological knowledge of 5-HT compounds, and poses timely questions as to how this field can move forward. The take home message is that the cardiovascular effects of 5-HT are markedly complex such that we have not yet answered the question of whether 5-HT is beneficial or detrimental to hypertension.
Authors:
Stephanie W Watts; Robert Patrick Davis
Related Documents :
6988155 - Newer antihypertensive agents.
6489195 - Indapamide. a review of its pharmacodynamic properties and therapeutic efficacy in hype...
2025785 - Predicting success in antihypertensive drug therapy: the importance of nondrug variables.
2685075 - The evolution of antihypertensive therapy: an overview of four decades of experience.
3192855 - The effects of acutely increased ventricular cavity pressure on intrinsic myocardial co...
25140155 - Systemic and renal oxidative stress in the pathogenesis of hypertension: modulation of ...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Review    
Journal Detail:
Title:  Cardiovascular therapeutics     Volume:  29     ISSN:  1755-5922     ISO Abbreviation:  Cardiovasc Ther     Publication Date:  2011 Feb 
Date Detail:
Created Date:  2011-01-18     Completed Date:  2011-04-22     Revised Date:  2014-04-07    
Medline Journal Info:
Nlm Unique ID:  101319630     Medline TA:  Cardiovasc Ther     Country:  England    
Other Details:
Languages:  eng     Pagination:  54-67     Citation Subset:  IM    
Copyright Information:
© 2010 Blackwell Publishing Ltd.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Arteries / physiology*
Blood Pressure
Humans
Hypertension / etiology*,  physiopathology
Receptors, Serotonin / physiology*
Serotonin / blood,  physiology
Grant Support
ID/Acronym/Agency:
F30 HL099024/HL/NHLBI NIH HHS; HL081115/HL/NHLBI NIH HHS; R01 HL107495/HL/NHLBI NIH HHS; R29 HL058489-05/HL/NHLBI NIH HHS
Chemical
Reg. No./Substance:
0/Receptors, Serotonin; 333DO1RDJY/Serotonin
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Soluble epoxide hydrolase inhibitors and heart failure.
Next Document:  Cryptic diversity of the bent-wing bat, Miniopterus schreibersii (Chiroptera: Vespertilionidae), in ...